Navigation Links
Major breakthrough toward the treatment of HIV/HAART-associated Lipodystrophy Syndrome
Date:12/5/2007

Montreal, December 5, 2007 Researchers in Montreal and Boston have identified a potential new treatment for the HIV/HAART*-associated Lipodystrophy Syndrome. This syndrome is a common side-effect of anti-retroviral medications to treat HIV infection. Dr. Julian Falutz, Director of the HIV Metabolic Clinic at the McGill University Health Centre (MUHC), and Dr. Steven Grinspoon, Director at the Massachusetts General Hospital Program in Nutritional Metabolism are publishing the results of their recent clinical trial in the December 6, 2007 issue of the New England Journal of Medicine.

The Lipodystrophy Syndrome consists of several metabolic disruptions that lead to abnormal lipid and glucose levels, as well as a generalized decrease in superficial fat tissues and an increase in deep abdominal fat. The observed body shape changes may cause significant impairment of patients quality-of-life leading many patients to stop taking their anti-retroviral medications. But the major health-threat related to the development of the Lipodystrophy Syndrome is an increased long-term cardiovascular risk.

Early in this decade, Dr. Falutz and Dr. Grinspoon began collaborating with Theratechnologies Inc., a Montreal-based biotechnology company that had developed a synthetic analogue of the naturally occurring growth hormone-releasing factor (GRF-tesamorelin). Its action is to regulate growth hormone levels that are important in controlling various metabolic processes. The effectiveness of this drug in reducing increased deep abdominal fat, and secondarily decreasing blood lipid levels, was initially confirmed in a small phase II study published in 2005. The current published results are from a large phase III Study conducted at 43 centers in the USA and Canada, which followed 412 patients for 6 months.

Its conclusions are decisive: Patients treated with tesamorelin saw their abdominal fat decrease by 15% on average, compared to a 5% average increase for the placebo group, explained Dr. Falutz. Also, the side-effects are minimal.

"This is a novel strategy to improve cardiovascular risk indices in HIV-infected patients and could represent a therapeutic breakthrough for many patients", stated Dr. Grinspoon.

A second confirmatory trial is ongoing in order to comply with US FDA (US Food and Drug Administration) regulations. If this second clinical study is as conclusive as the first, there is hope that patients will have tesamorelin available as a treatment option for HIV-associated lipodystrophy within the next couple of years., said Dr. Falutz.


'/>"/>

Contact: Isabelle Kling
isabelle.kling@muhc.mcgill.ca
514-934-1934
McGill University
Source:Eurekalert

Related medicine news :

1. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
2. Laboratory at UI plays major role in diagnosing cancer
3. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
4. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
5. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
6. Major grant advances UWs clinical and translational research enterprise
7. Major differences revealed in how local authorities in the UK support disabled people
8. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
9. Worldwide Probiotic Drink, Yakult(R), Launches in Its First Major U.S. Market
10. Ericom Provides Significant Cost-Savings for Major New York City Healthcare Organization
11. Eckert Seamans Announces Major Expansion in Philadelphia, West Chester and Harrisburg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of California Berkeley, and other leading institutions in announcing the launch of the ... to change the way animals are raised for food. , Founding members of ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
Breaking Medicine Technology: